5/15
01:25 pm
bolt
Rating for BOLT
Medium
Report
Rating for BOLT
5/15
12:24 pm
bolt
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Medium
Report
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
5/15
08:21 am
bolt
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "neutral" rating re-affirmed by analysts at Guggenheim.
Medium
Report
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "neutral" rating re-affirmed by analysts at Guggenheim.
5/15
08:21 am
bolt
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "neutral" rating re-affirmed by analysts at Guggenheim.
Medium
Report
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "neutral" rating re-affirmed by analysts at Guggenheim.
5/15
08:20 am
bolt
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $1.50 price target on the stock, down previously from $6.00.
Medium
Report
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $1.50 price target on the stock, down previously from $6.00.
5/15
08:20 am
bolt
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $1.50 price target on the stock, down previously from $6.00.
Medium
Report
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $1.50 price target on the stock, down previously from $6.00.
5/15
06:26 am
bolt
Rating for BOLT
Medium
Report
Rating for BOLT
5/15
06:26 am
bolt
Rating for BOLT
Medium
Report
Rating for BOLT
5/15
05:38 am
bolt
Rating for BOLT
High
Report
Rating for BOLT
3/22
11:19 am
bolt
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.